Newsroom

Download PDF CAMBRIDGE, Mass., Apr 12, 2011 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced the appointment of industry veteran Henri A. Termeer, outgoing chairman, president and chief executive officer of Genzyme Corporation, to its Board of Directors. “We are delighted that Henri will be joining our Board of Directors,” said Tuan Ha-Ngoc,

Download PDF CAMBRIDGE, Mass., Mar 31, 2011 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to participate in a panel titled “Prostate and GU Cancers” at 12:15 p.m. (EDT), as well as present a corporate overview on AVEO at 1:15 p.m. (EDT), at

Download PDF CAMBRIDGE, Mass., Mar 28, 2011 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that preclinical data on tivozanib, AVEO’s lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, and the company’s monoclonal antibody pipeline will be presented during poster sessions at the American Association

Download PDF CAMBRIDGE, Mass., Feb 23, 2011 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) today announced that members of the company’s management team are scheduled to present a corporate overview at several upcoming investment conferences. The conference and AVEO presentation details are as follows: Webcasts of AVEO’s presentations can be accessed by visiting the investors

Download PDF — AVEO to Receive $125 Million Upfront and $1.3 Billion in Potential Milestones —— Global 50/50 Profit Share with AVEO to Lead Commercialization in North America and Astellas to Lead Commercialization in Europe —— Agreement Accelerates Development of Tivozanib in Multiple Additional Cancer Indications — TOKYO & CAMBRIDGE, Mass., Feb 16, 2011 (BUSINESS

Download PDF CAMBRIDGE, Mass., Feb 16, 2011 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today reported consolidated 2010 financial results and reviewed key 2010 accomplishments. “Last year was a transformational year for AVEO with our initial public offering, rapid enrollment of our pivotal

Download PDF CAMBRIDGE, Mass., Feb 14, 2011 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that previously reported positive clinical data evaluating tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with renal cell carcinoma (RCC) will be featured in several poster

Download PDF CAMBRIDGE, Mass., Feb 10, 2011 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that financial results for the company’s fourth quarter and year ended December 31, 2010 will be released after the market closes on Wednesday, February 16, 2011. The AVEO management team will host a conference call discussing the company’s